BIO Plans Lobbying Push To Improve Payments For Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
The Biotechnology Industry Organization is adding its lobbying muscle to diagnostic industry efforts to improve payment policies for molecular tests, hoping for a warm reception from lawmakers who are already focused on personalized medicine issues.
You may also be interested in...
Next AdvaMed Chief Is BIO Exec Scott Whitaker
Whitaker, appointed as the next CEO of AdvaMed, currently runs day-to-day operations at the Biotechnology Innovation Organization and has held high-level posts at HHS. Among his accomplishments, Whitaker led the legislative office at HHS when the first device user fee bill was passed in 2002.
AdvaMedDx Steps Into Public Sphere: Director Details Diagnostics Priorities
The recently established diagnostics arm of AdvaMed had what its executive director called a coming out party last week.
AdvaMedDx Steps Into Public Sphere: Director Details Diagnostics Priorities
The recently established diagnostics arm of AdvaMed had what its executive director called a coming out party last week.